104

Development of Parkinson’s disease biomarkers

Year:
2010
Language:
english
File:
PDF, 355 KB
english, 2010
116

MAP1B rescues LRRK2 mutant-mediated cytotoxicity

Year:
2014
Language:
english
File:
PDF, 252 KB
english, 2014
123

TREATING SEVERE BRUXISM WITH BOTULINUM TOXIN

Year:
2000
Language:
english
File:
PDF, 69 KB
english, 2000
126

In vivoevidence of pathogenicity of VPS35 mutations in theDrosophila

Year:
2014
Language:
english
File:
PDF, 1.97 MB
english, 2014
131

Primary vs Postparalytic Hemifacial Spasm

Year:
2006
Language:
english
File:
PDF, 36 KB
english, 2006
133

Peripheral Edema and Dopamine Agonists in Parkinson Disease

Year:
2007
Language:
english
File:
PDF, 46 KB
english, 2007
134

Clinical Characteristics of Pramipexole-Induced Peripheral Edema

Year:
2000
Language:
english
File:
PDF, 149 KB
english, 2000
136

Genetic Testing in Spinocerebellar Ataxias

Year:
2001
Language:
english
File:
PDF, 85 KB
english, 2001
138

CHCHD2 and Parkinson's disease

Year:
2015
Language:
english
File:
PDF, 46 KB
english, 2015
139

Transient Paroxysmal Dyskinesia Associated with Focal Basal Ganglia Lesions

Year:
2003
Language:
english
File:
PDF, 88 KB
english, 2003
140

Evidence of Inflammatory System Involvement in Parkinson’s Disease

Year:
2014
Language:
english
File:
PDF, 253 KB
english, 2014
141

Neurovascular compression syndromes and hypertension: clinical relevance

Year:
2007
Language:
english
File:
PDF, 133 KB
english, 2007
145

Dopamine agonists and their role in Parkinson’s disease treatment

Year:
2003
Language:
english
File:
PDF, 296 KB
english, 2003
146

Considerations of Long-term Pain Evaluation Post–Deep Brain Stimulation Surgery

Year:
2015
Language:
english
File:
PDF, 46 KB
english, 2015
150

Restless Legs Syndrome: Clinical Features and Treatment

Year:
2000
Language:
english
File:
PDF, 1.08 MB
english, 2000